Important Facts of the News
- Around 3.5 million people in the UK are affected by rare diseases.
- Fewer than 5% of rare diseases currently have an approved treatment.
- The average time to diagnose a rare disease is 5.6 years.
- 30% of children with rare diseases pass away before age five.
- Cost of delayed diagnosis and limited treatment options is about £340 million annually.
- Total health-related disability costs amount to £4.7 billion per year.
- Annual economic loss due to rare diseases is estimated at £14.9 billion.
- MHRA plans to overhaul regulatory pathways for rare disease therapies.
- Reforms may introduce single early approval with real-world evidence monitoring.
- A new Rare Disease Consortium is supporting the reform framework.
A new policy paper has signalled a major shift in how rare disease therapies are developed and approved in the United Kingdom. The Medicines and Healthcare products Regulatory Agency has outlined plans to redesign the regulatory framework to help speed the journey of innovative treatments from the laboratory to patients.
Large Community, Limited Treatment Options
Rare diseases collectively affect about one in seventeen people in the UK, which amounts to approximately 3.5 million individuals. When caregivers are taken into account, the community living with the daily impact of rare conditions is larger than the population of London. However, fewer than 5% of rare diseases have any approved treatment. Many families experience long diagnostic delays, averaging more than five years, and a significant number of children do not survive beyond early childhood.
The lack of effective treatments also carries substantial economic consequences. Alongside healthcare and disability support costs, the reduced productivity associated with these conditions leads to an estimated annual economic loss of nearly £15 billion.
A New Rulebook to Address Longstanding Barriers
Developing therapies for rare diseases is challenging because patient groups are often small and scattered. Limited clinical understanding and difficulty in gathering strong evidence make clinical trials demanding and expensive. Current regulatory processes require separate approvals for trials and product licensing, increasing costs and slowing progress.
The proposed reforms aim to streamline this pathway. One of the ideas under consideration is a system that allows an early single approval, covering both the clinical trial stage and conditional marketing, based on compelling preliminary evidence. This would be paired with strict safety monitoring and regular assessments using real-world patient data.
Harnessing Advances in Genomics and Precision Medicine
Newer therapeutic methods, including gene-based interventions such as CRISPR and mRNA, offer scope for highly personalised treatment approaches. In some cases, therapies may be designed specifically for individual patients based on unique genetic characteristics. The updated framework aims to support such innovations by enabling more flexible regulatory pathways.
Collaboration at the Core of the Reform Effort
The MHRA is working with a newly formed Rare Disease Consortium that brings together patient groups, researchers, clinicians and industry partners. The goal is to ensure that the perspectives of affected communities shape the new system. Contributors include universities, NHS organisations, patient advocacy groups and biotechnology companies.
While the full framework is expected to be released next year, the paper represents a clear intention to accelerate access to new treatments while maintaining high standards of safety and effectiveness.